Early Oseltamivir Carboxylate Low Plasma Concentration in Patients Admitted to Intensive Care for Severe Influenza

NCT ID: NCT05375864

Last Updated: 2022-12-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 155 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-01
• Study Completion Date: 2025-03-01

Brief Summary

Introduction

Pandemic and seasonal influenza epidemics can be associated with a high degree of morbidity and mortality, especially in patients developing severe influenza pneumonitis with the acute respiratory distress syndrome (ARDS) or the less frequent fulminant myocarditis. Early administration (i.e. in the first 48 hours) of the neuraminidase inhibitor oseltamivir is associated with reduced mortality in patients hospitalized for severe influenza. Early oseltamivir administration, which can only be given orally (or through a nasogastric tube), is thus recommended by the World Health Organization in patients hospitalized for severe influenza, including those requiring intensive care (ICU) admission. However, enteric absorption may be compromised in critically ill patients due to impaired gut function.

Hypothesis/Objective

The hypothese is that, in patients admitted for severe influenza, early (i.e., measured at the 48th hour of treatment initiation) oseltamivir carboxylate (OC) low plasma concentration would be: 1) associated with a poor prognosis; and 2) detectable by carrying out a paracetamol absorption test (PAT).

The main objective of the study is to determine the prognostic impact of early OC low plasma concentration in patients admitted to the intensive care unit (ICU) for severe influenza.

Primary outcome measure: Number of live ventilator-free days at 28-day in patients with versus without OC low plasma concentration.

Detailed Description

Methods

Prospective cohort study conducted in 22 French intensive care units. Adult patients admitted to the ICU for severe influenza requiring invasive mechanical ventilation and treated with oseltamivir through a gastric tube for less than 24 hours will be included.

After inclusion, oseltamivir treatment will be continued through a gastric tube (75mg x 2 /day). After the 4th administration, plasma peak concentration of oseltamivir phosphate (OP) will be dosed at 60 minutes (CmaxOP) and plasma residual concentration of OC will be dosed at 12 hours (just before the 5th dose) (CresOC). A paracetamol absorption test will also be performed at the same time (consisting in the measurement of plasma paracetamol concentration 60 minutes after enteral loading with 1000 mg of paracetamol). CmaxOP and CresOC will also be measured at day 3 and 5 in order to realize pharmacokinetic analysis. Nasal swabs will be performed at inclusion (day 1) and day 5 for viral load quantification and viral strain sequencing (detection of the H275Y mutation). Clinical and biological variables will be collected from day 1 to day 90.

Conditions

Severe Influenza

Keywords

Influenza; Intensive Care Unit; oseltamivir; paracetamol absorption test

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SCREENING
• Blinding Strategy: NONE

Study Groups

Paracetamol absorption test

Group Type: EXPERIMENTAL

Absorption test

Intervention Type: OTHER

Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.

Interventions

Absorption test

Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adult patients
• Confirmed severe influenza infection requiring intensive care with tracheal intubation for invasive mechanical ventilation (influenza ARDS with or without bacterial co-infection, cardiorespiratory decompensation of influenza origin, influenza myocarditis)
• Oseltamivir treatment administered through a gastric tube initiated since less than 24 hours (i.e. maximum two doses administered)
• Affiliation to a social security system or beneficiary (excluding AME)
• Written consent obtained (or under emergency procedures)

Exclusion Criteria

• Pregnancy or breastfeeding women
• Weight less than 40 kg
• Zanamivir or other antiviral effective treatment received for more than 24 hours
• Other respiratory virus infection (including SARS-CoV-2)
• Contra-indication to esophageal tube insertion or use
• Child-Pugh C cirrhosis or severe liver insufficiency
• Paracetamol allergy
• Ongoing participation in an interventional therapeutic trial (medicine that may interact with paracetamol or oseltamivir)
• Patient benefiting from AME (State Medical Aid)
• Patient deprived of liberty or under legal protection (guardianship or curatorship)
• For patients not included in an emergency situation: Inability, according to the investigator, to understand or refusal to sign the informed consent to participate in the study (non-French-speaking patient).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anne-Fleur Haudebourg, M.D

Role: STUDY_DIRECTOR

Assistance Publique Hôpitaux de Paris - CHU Henri Mondor

Locations

Anne-Fleur Haudebourg

Créteil, , France

Countries

France

Central Contacts

Anne-Fleur Haudebourg, M.D

Role: CONTACT

Phone: 01 45 17 85 06

Email: annefleur.maignant@aphp.fr

Nicolas de Prost, M.D., Ph.D

Role: CONTACT

Phone: 01 45 17 86 37

Email: nicolas.de-prost@aphp.fr

Facility Contacts

Anne-Fleur Haudebourg, M.D

Role: primary

Nicolas De PROST, M.D., Ph.D

Role: backup

Other Identifiers

2022-002377-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

APHP210090

Identifier Type: -

Identifier Source: org_study_id